Core Insights - Esperion Therapeutics, Inc. has received a consensus rating of "Moderate Buy" from seven brokerages, with an average 1-year price target of $8.00 [2] Analyst Ratings - Citigroup and Cantor Fitzgerald have restated "market outperform" and "overweight" ratings respectively on November 12th [3] - Wall Street Zen downgraded the stock from "buy" to "hold" [3] - Weiss Ratings issued a "sell (d-)" rating on January 22nd [3] - Piper Sandler initiated coverage with an "overweight" rating and a target price of $9.00 [3] Stock Performance - Esperion Therapeutics stock opened at $3.43, with a 12-month low of $0.69 and a high of $4.18 [4] - The stock has a market cap of $819.98 million, a price-to-earnings ratio of -6.86, and a PEG ratio of 0.72 [4] Insider Transactions - CFO Benjamin Halladay sold 7,337 shares at an average price of $3.67, totaling $26,926.79, reducing his ownership by 1.55% [5] - Insiders have sold 15,543 shares worth $55,709 in the last ninety days, with insiders owning 1.70% of the stock [5] Institutional Trading - Vanguard Group Inc. increased its stake by 23.6%, now owning 14,945,454 shares valued at $55.3 million [6] - Two Seas Capital LP raised its holdings by 22.1%, owning 11,902,521 shares worth $44.04 million [6] - Wasatch Advisors LP increased its stake by 33.8%, now holding 9,445,759 shares valued at $34.95 million [6] - State Street Corp lifted its holdings by 32.4%, owning 5,930,296 shares valued at $21.94 million [6] - Geode Capital Management LLC boosted its holdings by 20.8%, now owning 5,737,651 shares worth $21.23 million [6] - Institutional investors and hedge funds own 47.39% of the company's stock [6] Company Overview - Esperion Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral LDL-C-lowering therapies [7] - The company targets cholesterol biosynthesis pathways to address atherosclerotic cardiovascular disease [8] - Its lead product, NEXLETOL (bempedoic acid), is an approved oral ACL inhibitor [8]